SELLAS Life Sciences Group, Inc.

NasdaqCM SLS

SELLAS Life Sciences Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

SELLAS Life Sciences Group, Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SELLAS Life Sciences Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -105.34%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: SLS

SELLAS Life Sciences Group, Inc.

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
IPO Date	March 12, 2008
Location	United States
Headquarters	Times Square Tower
Employees	16
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Key trends

Past 5 years